INTRODUCTION {#s1}
============

Multidrug-resistant (MDR) Gram-positive organisms are major human pathogens, causing both health care-associated and community-acquired infections. Clinically important antimicrobial-resistant Gram-positive pathogens include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and Streptococcus pneumoniae. In fact, all three have recently been highlighted among the Gram-positive pathogens classified as serious or high public health threats by the Centers for Disease Control and Prevention (CDC) ([@B1]) and the World Health Organization (WHO) ([@B2]).

Eravacycline is a novel, fully synthetic fluorocycline antibiotic recently approved by U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of complicated intra-abdominal infections (cIAI), including those caused by MDR pathogens ([@B3], [@B4]; <https://clinicaltrials.gov/ct2/show/NCT01844856>). Additionally, eravacycline has been demonstrated to have *in vivo* efficacy as a treatment in murine models of systemic, thigh, and lung infection and pyelonephritis ([@B4], [@B6], [@B7]).

Eravacycline is comprised of a tetracycline core with two novel modifications: a fluorine atom at the C-7 position and a pyrrolidinoacetamido group at the C-9 position, both of which are on the D ring ([@B4], [@B8]). These novel modifications confer enhanced *in vitro* activity compared to that of other tetracyclines against resistant Gram-negative and Gram-positive bacteria, and the pyrrolidinoacetamido group allows for increased ribosomal binding and steric hindrance to avoid ribosome protection-based tetracycline resistance.

Eravacycline inhibits bacterial protein synthesis (i.e., acyl-tRNA transfer) by binding to the 30S ribosomal subunit ([@B9]). Eravacycline demonstrates potent broad-spectrum activity against Gram-positive cocci and Gram-negative bacilli (except Pseudomonas aeruginosa and *Burkholderia* spp.), including anaerobes, as well as atypical bacterial pathogens and Neisseria gonorrhoeae ([@B3], [@B10][@B11][@B15]), and does not exhibit a loss of antibacterial activity against isolates expressing tetracycline ribosomal protection genes or most tetracycline efflux resistance genes ([@B9], [@B10], [@B13]).

The objective of the current study was to determine the *in vitro* activity of eravacycline relative to that of other antimicrobial agents using a representative global collection of clinical isolates of Gram-positive bacteria.

RESULTS AND DISCUSSION {#s2}
======================

A total of 10,511 Gram-positive aerobic isolates collected between 2013 and 2017 were included in this study. The MIC distributions and the cumulative percentage of selected isolates of Gram-positive bacteria tested inhibited by eravacycline are shown in [Table 1](#T1){ref-type="table"}. The MIC~90~ of eravacycline for isolates of S. aureus was 0.12 μg/ml irrespective of whether the isolates were MRSA or methicillin-susceptible S. aureus (MSSA). The eravacycline MIC~90~ values for the coagulase-negative staphylococci Staphylococcus epidermidis and Staphylococcus haemolyticus, including the methicillin-resistant subsets, were ≤0.5 μg/ml. The eravacycline MIC~90~ for Enterococcus faecalis was 0.06 μg/ml, with a 1-doubling-dilution shift being seen for vancomycin-resistant E. faecalis. The eravacycline MIC~90~ for Enterococcus faecium was 0.06 μg/ml, regardless of its vancomycin susceptibility. Eravacycline exhibited MIC~90~ results of ≤0.06 μg/ml when tested against beta-hemolytic and viridans group streptococci as well as an MIC~90~ of 0.015 μg/ml for Streptococcus pneumoniae.

###### 

Cumulative percentage of clinical isolates of staphylococci, enterococci, and streptococci tested from 2013 to 2017 inhibited by eravacycline, by MIC

  Organism[^*g*^](#T1F7){ref-type="table-fn"}                                                        No. of isolates   Cumulative % of isolates inhibited by the following eravacycline MIC (μg/ml)[^*a*^](#T1F1){ref-type="table-fn"}:                                                                        
  -------------------------------------------------------------------------------------------------- ----------------- ------------------------------------------------------------------------------------------------------------------ ----- ------ ------ ------ ------ ------ ------ ------ ------ ------ -----
  S. aureus[^*b*^](#T1F2){ref-type="table-fn"}                                                       2,588                                                                                                                                             0.4    3.8    33.4   84.5   94.8   97.6   99.4   100    
      S. aureus, MR[^*b*^](#T1F2){ref-type="table-fn"}                                               1,304                                                                                                                                             0.2    4.1    32.8   80.8   91.6   95.5   98.8   100    
      S. aureus, MS[^*b*^](#T1F2){ref-type="table-fn"}                                               1,284                                                                                                                                             0.5    3.5    34.0   88.3   98.0   99.8   100           
  S. epidermidis[^*b*^](#T1F2){ref-type="table-fn"}                                                  1,012                                                                                                                                             1.4    11.5   28.2   45.7   63.4   84.6   97.1   99.8   100
      S. epidermidis, MR[^*b*^](#T1F2){ref-type="table-fn"}^,^[^*c*^](#T1F3){ref-type="table-fn"}    480                                                                                                                                               1.9    10.8   30.8   43.8   66.7   90.4   97.9   99.8   100
      S. epidermidis, MS[^*b*^](#T1F2){ref-type="table-fn"}^,^[^*c*^](#T1F3){ref-type="table-fn"}    255                                                                                                                                               2.0    24.3   47.8   59.6   75.7   96.9   99.6   99.6   100
  S. haemolyticus[^*b*^](#T1F2){ref-type="table-fn"}                                                 731                                                                                                                                               1.2    13.5   34.6   45.6   64.8   89.9   96.0   98.8   100
      S. haemolyticus, MR[^*b*^](#T1F2){ref-type="table-fn"}^,^[^*c*^](#T1F3){ref-type="table-fn"}   440                                                                                                                                               0.5    11.4   30.9   36.8   60.2   90.0   95.2   98.0   100
      S. haemolyticus, MS[^*b*^](#T1F2){ref-type="table-fn"}^,^[^*c*^](#T1F3){ref-type="table-fn"}   134                                                                                                                                               5.2    35.8   76.9   85.8   94.8   97.8   99.3   100    
  E. faecalis                                                                                        1,586                                                                                                                                             0.2    2.6    28.9   94.5   99.4   99.7   100           
      E. faecalis, VR[^*d*^](#T1F4){ref-type="table-fn"}                                             59                                                                                                                                                              23.7   89.8   98.3   100                  
      E. faecalis, VS                                                                                1,505                                                                                                                                             0.2    2.7    29.4   94.8   99.5   99.7   100           
  E. faecium                                                                                         1,221                                                                                                                                             0.6    4.3    60.2   95.0   97.7   99.1   99.8   100    
      E. faecium, VR[^*d*^](#T1F4){ref-type="table-fn"}                                              510                                                                                                                                               0.6    3.7    54.9   93.1   96.1   98.0   99.6   100    
      E. faecium, VS                                                                                 702                                                                                                                                               0.6    4.6    63.8   96.3   98.9   99.9   100           
  S. pneumoniae[^*e*^](#T1F5){ref-type="table-fn"}                                                   596               0.8                                                                                                                2.0   14.8   73.0   97.8   100                                       
  S. agalactiae                                                                                      1,239                                                                                                                                             0.7    13.4   70.5   98.0   99.8   100                  
  S. pyogenes                                                                                        1,192                                                                                                                                      0.2    3.6    47.8   96.0   100                                
  S. anginosus group[^*f*^](#T1F6){ref-type="table-fn"}                                              346               5.2                                                                                                                5.5   8.7    19.9   46.5   86.4   99.1   100                         
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The MIC~90~ is shaded gray.

For staphylococci, the lowest dilution of eravacycline tested was 0.008 μg/ml.

Defined using oxacillin MICs, which were available only for 2015 to 2017.

Defined using CLSI breakpoint criteria.

Collected only in 2013 to 2014 and 2017.

The S. anginosus group (*n* = 346) includes S. anginosus (*n* = 302), S. constellatus (*n* = 36), S. intermedius (*n* = 7), and S. intermedius/S. milleri (*n* = 1).

MR, methicillin resistant; MS, methicillin susceptible; VR, vancomycin resistant; VS, vancomycin susceptible.

[Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, and [4](#T4){ref-type="table"} provide details on the *in vitro* activities of eravacycline and the comparator agents against staphylococci, enterococci, and streptococci, respectively, including percent susceptibility according to the CLSI and EUCAST breakpoints. The highest rates of nonsusceptibility in MRSA were reported for azithromycin, clindamycin, and levofloxacin (75.9%, 38.3%, and 65.9%, respectively, by CLSI criteria), while resistance rates were \<1% for linezolid, daptomycin, and vancomycin ([Table 2](#T2){ref-type="table"}). For compounds of the tetracycline class, tigecycline and minocycline, resistance rates were approximately 2 to 12% across FDA/CLSI and EUCAST breakpoints. Comparatively, due to overall lower breakpoints for eravacycline, the nonsusceptible rate was nearly 20% by the FDA criteria and 4.5% by the EUCAST criteria, but the MIC~90~ value of eravacycline was 2-fold lower than that of tigecycline. Similarly, for E. faecalis the nonsusceptibility rates to linezolid and daptomycin were \<1% and 5.6%, respectively, while the rates were 2% and 53%, respectively, for E. faecium ([Table 3](#T3){ref-type="table"}). Vancomycin retained activity against E. faecalis, with a resistance rate of 4.9%, but it was generally ineffective against E. faecium, in which the rate of resistance exceeded 40%. Both species of enterococci were resistant to minocycline, with nonsusceptibility rates ranging from 49 to 72%. While eravacycline and tigecycline nonsusceptibility rates were about 1 to 5%, the MIC~90~ of tigecycline was 2 doubling dilutions higher than that of eravacycline. Notably, the rates of resistance for the comparators in this study were similar to those seen in other global surveillance studies ([@B16], [@B17]).

###### 

*In vitro* activity of eravacycline and comparator agents against staphylococci, cumulative 2013 to 2017 data[^*d*^](#T2F4){ref-type="table-fn"}

  Organism                                                     Drug                      No. of isolates   MIC (μg/ml)   \% susceptible                                                             
  ------------------------------------------------------------ ------------------------- ----------------- ------------- ---------------- --------------- ----------------------------------------- -----------------------------------------
  S. aureus                                                    Eravacycline              2,588             0.06          0.12             ≤0.008 to 1     84.5[^*a*^](#T2F1){ref-type="table-fn"}   97.6
                                                               Amoxicillin-clavulanate   2,588             \>1           \>1              ≤0.12 to \>1    NA                                        NA
                                                               Azithromycin              2,588             \>4           \>4              ≤0.25 to \>4    49.3                                      47.8
                                                               Ceftaroline               1,076             0.5           1                ≤0.06 to \>4    94.1                                      94.1
                                                               Ceftriaxone               980               16            \>64             1 to \>64       NA                                        NA
                                                               Clindamycin               1,608             0.12          \>2              ≤0.03 to \>2    78.3                                      78.2
                                                               Daptomycin                2,588             0.5           1                ≤0.06 to 4      99.8                                      99.8
                                                               Gentamicin                532               0.25          0.5              ≤0.06 to \>8    92.5                                      92.1
                                                               Levofloxacin              2,588             0.25          \>4              ≤0.03 to \>4    62.1                                      62.1
                                                               Linezolid                 2,588             2             2                ≤0.5 to 2       100                                       100
                                                               Minocycline               2,587             0.12          0.25             ≤0.06 to \>8    95.2                                      93.2
                                                               Oxacillin                 1,608             \>2           \>2              ≤0.06 to \>2    49.6                                      49.6
                                                               Penicillin                2,588             \>2           \>2              ≤0.12 to \>2    13.4                                      13.4
                                                               Tetracycline              2,588             0.25          \>16             ≤0.06 to \>16   87.6                                      86.1
                                                               Tigecycline               2,588             0.12          0.25             0.03 to 2       98.6[^*a*^](#T2F1){ref-type="table-fn"}   98.6
                                                               Vancomycin                1,608             1             1                ≤0.25 to 2      100                                       100
      S. aureus, MR                                            Eravacycline              1,304             0.06          0.12             ≤0.008 to 1     80.8[^*a*^](#T2F1){ref-type="table-fn"}   95.5
                                                               Amoxicillin-clavulanate   1,304             \>1           \>1              0.5 to \>1      NA                                        NA
                                                               Azithromycin              1,304             \>4           \>4              ≤0.25 to \>4    24.1                                      23.1
                                                               Ceftaroline               548               1             2                0.12 to \>4     88.3                                      88.3
                                                               Ceftriaxone               493               \>64          \>64             4 to \>64       NA                                        NA
                                                               Clindamycin               811               0.12          \>2              ≤0.03 to \>2    61.7                                      61.7
                                                               Daptomycin                1,304             0.5           1                ≤0.06 to 4      99.6                                      99.6
                                                               Gentamicin                263               0.25          \>8              0.12 to \>8     85.6                                      85.2
                                                               Levofloxacin              1,304             \>4           \>4              0.06 to \>4     34.1                                      34.1
                                                               Linezolid                 1,304             2             2                ≤0.5 to 2       100                                       100
                                                               Minocycline               1,303             0.12          4                ≤0.06 to \>8    91.8                                      88.2
                                                               Oxacillin                 811               \>2           \>2              1 to \>2        0.1                                       0.1
                                                               Penicillin                1,304             \>2           \>2              ≤0.12 to \>2    0.2                                       0.2
                                                               Tetracycline              1,304             0.25          \>16             ≤0.06 to \>16   82.0                                      79.8
                                                               Tigecycline               1,304             0.12          0.25             0.03 to 2       97.5[^*a*^](#T2F1){ref-type="table-fn"}   97.5
                                                               Vancomycin                811               1             1                ≤0.25 to 2      100                                       100
      S. aureus, MS                                            Eravacycline              1,284             0.06          0.12             ≤0.008 to 0.5   88.3[^*a*^](#T2F1){ref-type="table-fn"}   99.8
                                                               Amoxicillin-clavulanate   1,284             1             \>1              ≤0.12 to \>1    NA                                        NA
                                                               Azithromycin              1284              1             \>4              ≤0.25 to \>4    74.9                                      73.0
                                                               Ceftaroline               528               0.25          0.25             ≤0.06 to 0.5    100                                       100
                                                               Ceftriaxone               487               4             8                1 to \>64       NA                                        NA
                                                               Clindamycin               797               0.06          0.12             ≤0.03 to \>2    95.2                                      95.0
                                                               Daptomycin                1,284             0.5           0.5              0.12 to 2       99.9                                      99.9
                                                               Gentamicin                269               0.25          0.5              ≤0.06 to \>8    99.3                                      98.9
                                                               Levofloxacin              1,284             0.25          1                ≤0.03 to \>4    90.5                                      90.5
                                                               Linezolid                 1,284             2             2                ≤0.5 to 2       100                                       100
                                                               Minocycline               1,284             0.12          0.12             ≤0.06 to \>8    98.7                                      98.3
                                                               Oxacillin                 797               0.25          0.5              ≤0.06 to \>2    99.9                                      99.9
                                                               Penicillin                1,284             2             \>2              ≤0.12 to \>2    26.8                                      26.8
                                                               Tetracycline              1,284             0.25          0.5              ≤0.06 to \>16   93.4                                      92.5
                                                               Tigecycline               1,284             0.12          0.25             0.03 to 1       99.7[^*a*^](#T2F1){ref-type="table-fn"}   99.7
                                                               Vancomycin                797               1             1                ≤0.25 to 2      100                                       100
  S. epidermidis                                               Eravacycline              1,012             0.12          0.5              ≤0.008 to 2     45.7[^*a*^](#T2F1){ref-type="table-fn"}   84.6[^*b*^](#T2F2){ref-type="table-fn"}
                                                               Amoxicillin-clavulanate   1,012             \>1           \>1              ≤0.12 to \>1    NA                                        NA
                                                               Azithromycin              1,012             \>4           \>4              ≤0.25 to \>4    37.2                                      36.9
                                                               Ceftaroline               529               0.25          0.5              ≤0.06 to \>4    NA                                        NA
                                                               Ceftriaxone               277               16            \>64             ≤0.5 to \>64    NA                                        NA
                                                               Clindamycin               735               0.06          \>2              ≤0.03 to \>2    72.0                                      68.6
                                                               Daptomycin                1,012             0.5           1                ≤0.06 to 4      99.5                                      99.5
                                                               Gentamicin                206               0.12          \>8              ≤0.06 to \>8    62.6                                      55.8
                                                               Levofloxacin              1,012             2             \>4              0.06 to \>4     45.6                                      45.6
                                                               Linezolid                 1,012             1             2                ≤0.5 to \>8     98.5                                      98.5
                                                               Minocycline               1,012             0.12          0.5              ≤0.06 to \>8    99.6                                      98.7
                                                               Oxacillin                 735               2             \>2              ≤0.06 to \>2    34.7                                      34.7
                                                               Penicillin                1,012             \>2           \>2              ≤0.12 to \>2    11.1                                      NA
                                                               Tetracycline              1,012             1             \>16             ≤0.06 to \>16   85.7                                      66.5
                                                               Tigecycline               1,012             0.12          0.5              ≤0.015 to 1     97.5[^*a*^](#T2F1){ref-type="table-fn"}   97.5
                                                               Vancomycin                735               1             2                0.5 to 2        100                                       100
      S. epidermidis, MR[^*c*^](#T2F3){ref-type="table-fn"}    Eravacycline              480               0.12          0.25             ≤0.008 to 2     43.8[^*a*^](#T2F1){ref-type="table-fn"}   90.4[^*b*^](#T2F2){ref-type="table-fn"}
                                                               Amoxicillin-clavulanate   480               \>1           \>1              ≤0.12 to \>1    NA                                        NA
                                                               Azithromycin              480               \>4           \>4              ≤0.25 to \>4    30.6                                      30.4
                                                               Ceftaroline               326               0.5           1                ≤0.06 to \>4    NA                                        NA
                                                               Clindamycin               480               0.12          \>2              ≤0.03 to \>2    61.7                                      57.7
                                                               Daptomycin                480               0.5           0.5              ≤0.06 to 1      100                                       100
                                                               Gentamicin                154               4             \>8              ≤0.06 to \>8    52.0                                      44.2
                                                               Levofloxacin              480               4             \>4              0.06 to \>4     26.3                                      26.3
                                                               Linezolid                 480               ≤0.5          1                ≤0.5 to \>4     97.7                                      97.7
                                                               Minocycline               480               0.12          0.5              ≤0.06 to \>8    99.4                                      98.8
                                                               Oxacillin                 480               \>2           \>2              0.5 to \>2      0.0                                       0.0
                                                               Penicillin                480               \>2           \>2              ≤0.12 to \>2    1.3                                       NA
                                                               Tetracycline              480               1             \>16             ≤0.06 to \>16   84.8                                      70.2
                                                               Tigecycline               480               0.12          0.25             ≤0.015 to 1     99.0[^*a*^](#T2F1){ref-type="table-fn"}   99.0
                                                               Vancomycin                480               1             2                0.5 to 2        100                                       100
      S. epidermidis, MS[^*c*^](#T2F3){ref-type="table-fn"}    Eravacycline              255               0.06          0.25             ≤0.008 to 2     59.6[^*a*^](#T2F1){ref-type="table-fn"}   96.9[^*b*^](#T2F2){ref-type="table-fn"}
                                                               Amoxicillin-clavulanate   255               0.25          0.5              ≤0.12 to \>1    NA                                        NA
                                                               Azithromycin              255               0.5           \>4              ≤0.25 to \>4    53.3                                      52.9
                                                               Ceftaroline               203               ≤0.06         0.12             ≤0.06 to 0.5    NA                                        NA
                                                               Clindamycin               255               0.06          0.5              ≤0.03 to \>2    91.4                                      89.0
                                                               Daptomycin                255               0.5           0.5              ≤0.06 to 1      100                                       100
                                                               Gentamicin                52                ≤0.06         0.25             ≤0.06 to \>8    94.2                                      90.4
                                                               Levofloxacin              255               0.25          \>4              0.06 to \>4     81.6                                      81.6
                                                               Linezolid                 255               ≤0.5          1                ≤0.5 to \>4     99.6                                      99.6
                                                               Minocycline               255               0.12          0.25             ≤0.06 to 4      100                                       99.6
                                                               Oxacillin                 255               0.12          0.12             ≤0.06 to 0.25   100                                       100
                                                               Penicillin                255               0.5           2                ≤0.12 to \>2    29.4                                      NA
                                                               Tetracycline              255               0.5           4                ≤0.06 to \>16   90.6                                      80.8
                                                               Tigecycline               255               0.12          0.25             0.03 to 1       99.6[^*a*^](#T2F1){ref-type="table-fn"}   99.6
                                                               Vancomycin                255               1             2                0.5 to 2        100                                       100
  S. haemolyticus                                              Eravacycline              731               0.12          0.5              ≤0.008 to 2     45.6[^*a*^](#T2F1){ref-type="table-fn"}   89.9[^*b*^](#T2F2){ref-type="table-fn"}
                                                               Amoxicillin-clavulanate   731               \>1           \>1              ≤0.12 to \>1    NA                                        NA
                                                               Azithromycin              731               \>4           \>4              ≤0.25 to \>4    20.4                                      20.1
                                                               Ceftaroline               426               1             2                ≤0.06 to \>4    NA                                        NA
                                                               Ceftriaxone               157               \>64          \>64             1 to \>64       NA                                        NA
                                                               Clindamycin               574               0.06          \>2              ≤0.03 to \>2    80.0                                      79.6
                                                               Daptomycin                731               0.5           0.5              0.12 to 2       99.9                                      99.9
                                                               Gentamicin                148               8             \>8              ≤0.06 to \>8    39.9                                      29.1
                                                               Levofloxacin              731               \>4           \>4              0.06 to \>4     28.9                                      28.9
                                                               Linezolid                 732               1             2                ≤0.5 to \>8     99.9                                      99.9
                                                               Minocycline               731               0.12          0.25             ≤0.06 to 8      99.7                                      98.1
                                                               Oxacillin                 574               \>2           \>2              ≤0.06 to \>2    23.3                                      23.3
                                                               Penicillin                731               \>2           \>2              ≤0.12 to \>2    17.2                                      NA
                                                               Tetracycline              731               1             \>16             ≤0.06 to \>16   81.0                                      69.8
                                                               Tigecycline               731               0.25          0.5              0.03 to 2       95.9[^*a*^](#T2F1){ref-type="table-fn"}   95.9
                                                               Vancomycin                574               1             2                ≤0.25 to 4      100                                       100
      S. haemolyticus, MR[^*c*^](#T2F3){ref-type="table-fn"}   Eravacycline              440               0.12          0.25             ≤0.008 to 2     36.8[^*a*^](#T2F1){ref-type="table-fn"}   90.0[^*b*^](#T2F2){ref-type="table-fn"}
                                                               Amoxicillin-clavulanate   440               \>1           \>1              ≤0.12 to \>1    NA                                        NA
                                                               Azithromycin              440               \>4           \>4              ≤0.25 to \>4    9.8                                       9.8
                                                               Ceftaroline               317               2             2                0.12 to \>4     NA                                        NA
                                                               Clindamycin               440               0.06          \>2              ≤0.03 to \>2    75.0                                      74.6
                                                               Daptomycin                440               0.5           0.5              0.12 to 1       100                                       100
                                                               Gentamicin                123               \>8           \>8              ≤0.06 to \>8    30.1                                      17.9
                                                               Levofloxacin              440               \>4           \>4              0.06 to \>4     13.0                                      13.0
                                                               Linezolid                 441               1             1                ≤0.5 to 2       100                                       100
                                                               Minocycline               440               0.25          0.25             ≤0.06 to 8      99.8                                      97.5
                                                               Oxacillin                 440               \>2           \>2              0.5 to \>2      0.0                                       0.0
                                                               Penicillin                440               \>2           \>2              ≤0.12 to \>2    1.6                                       NA
                                                               Tetracycline              440               1             \>16             0.12 to \>16    82.3                                      71.8
                                                               Tigecycline               440               0.25          0.5              0.06 to 2       95.5[^*a*^](#T2F1){ref-type="table-fn"}   95.5
                                                               Vancomycin                440               1             2                ≤0.25 to 4      100                                       100
      S. haemolyticus, MS[^*c*^](#T2F3){ref-type="table-fn"}   Eravacycline              134               0.03          0.12             ≤0.008 to 1     85.8[^*a*^](#T2F1){ref-type="table-fn"}   97.8[^*b*^](#T2F2){ref-type="table-fn"}
                                                               Amoxicillin-clavulanate   134               ≤0.12         0.5              ≤0.12 to \>1    NA                                        NA
                                                               Azithromycin              134               0.5           \>4              ≤0.25 to \>4    54.5                                      53.0
                                                               Ceftaroline               109               0.25          0.25             ≤0.06 to 2      NA                                        NA
                                                               Clindamycin               134               0.06          0.25             ≤0.03 to \>2    96.3                                      96.3
                                                               Daptomycin                134               0.25          0.5              0.12 to 0.5     100                                       100
                                                               Gentamicin                25                ≤0.06         8                ≤0.06 to \>8    88.0                                      84.0
                                                               Levofloxacin              134               0.12          4                0.06 to \>4     85.1                                      85.1
                                                               Linezolid                 134               ≤0.5          1                ≤0.5 to 2       100                                       100
                                                               Minocycline               134               ≤0.06         0.25             ≤0.06 to 0.5    100                                       100
                                                               Oxacillin                 134               0.12          0.25             ≤0.06 to 0.25   100                                       100
                                                               Penicillin                134               ≤0.12         1                ≤0.12 to \>2    74.6                                      NA
                                                               Tetracycline              134               0.25          \>16             ≤0.06 to \>16   79.1                                      78.4
                                                               Tigecycline               134               0.12          0.25             0.06 to 0.5     100[^*a*^](#T2F1){ref-type="table-fn"}    100
                                                               Vancomycin                134               0.5           1                ≤0.25 to 2      100                                       100
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U.S. Food and Drug Administration (FDA) MIC interpretative breakpoints were used in place of CLSI MIC breakpoints for eravacycline (≤0.06 μg/ml) and tigecycline (≤0.5 μg/ml) ([@B21]), as none currently exist. FDA eravacycline and tigecycline breakpoints for S. aureus were applied to the tested coagulase-negative *Staphylococcus* species.

EUCAST eravacycline breakpoints for S. aureus (≤0.25 μg/ml) were applied to the coagulase-negative *Staphylococcus* species tested.

Defined using oxacillin MICs, which were available only for 2015 to 2017.

MR, methicillin resistant; MS, methicillin susceptible; NA, MIC breakpoint not available.

###### 

*In vitro* activity of eravacycline and comparator agents against enterococci, cumulative 2013 to 2017 data[^*c*^](#T3F3){ref-type="table-fn"}

  Organism              Drug                      No. of isolates   MIC (μg/ml)   \% susceptible                                                             
  --------------------- ------------------------- ----------------- ------------- ---------------- --------------- ----------------------------------------- -----------------------------------------
  E. faecalis           Eravacycline              1,586             0.06          0.06             0.008 to 0.5    94.5[^*a*^](#T3F1){ref-type="table-fn"}   99.4
                        Amoxicillin-clavulanate   1,586             1             1                ≤0.12 to \>1    NA                                        99.9[^*b*^](#T3F2){ref-type="table-fn"}
                        Ampicillin                1,085             1             2                ≤0.25 to \>8    99.3                                      99.3
                        Azithromycin              501               \>8           \>8              ≤0.12 to \>8    NA                                        NA
                        Ceftriaxone               501               \>64          \>64             ≤0.5 to \>64    NA                                        NA
                        Daptomycin                1,586             1             2                ≤0.06 to 8      94.4                                      NA
                        Levofloxacin              1,586             1             \>8              ≤0.03 to \>8    69.1                                      69.5
                        Linezolid                 1,586             2             2                ≤0.5 to \>4     99.4                                      99.9
                        Minocycline               1,586             \>8           \>8              ≤0.03 to \>8    27.8                                      NA
                        Penicillin                1,586             2             4                ≤0.12 to \>8    97.6                                      NA
                        Tetracycline              1,586             \>32          \>32             ≤0.06 to \>32   22.3                                      NA
                        Tigecycline               1,586             0.12          0.25             ≤0.015 to 8     94.8[^*a*^](#T3F1){ref-type="table-fn"}   94.8
                        Vancomycin                1,582             1             2                0.12 to \>32    95.1                                      95.1
      E. faecalis, VR   Eravacycline              59                0.06          0.12             0.03 to 0.25    89.8[^*a*^](#T3F1){ref-type="table-fn"}   98.3
                        Amoxicillin-clavulanate   59                1             \>1              0.5 to \>1      NA                                        98.3[^*b*^](#T3F2){ref-type="table-fn"}
                        Ampicillin                34                1             2                1 to \>8        97.1                                      97.1
                        Azithromycin              25                \>8           \>8              2 to \>8        NA                                        NA
                        Ceftriaxone               25                \>64          \>64             4 to \>64       NA                                        NA
                        Daptomycin                59                1             2                0.5 to 4        96.6                                      NA
                        Levofloxacin              59                \>8           \>8              0.5 to \>8      5.1                                       5.1
                        Linezolid                 59                1             2                ≤0.5 to 2       100                                       100
                        Minocycline               59                \>8           \>8              0.06 to \>8     15.3                                      NA
                        Penicillin                59                4             8                1 to \>8        96.6                                      NA
                        Tetracycline              59                \>32          \>32             0.25 to \>32    8.5                                       NA
                        Tigecycline               59                0.12          0.25             0.06 to 1       94.9[^*a*^](#T3F1){ref-type="table-fn"}   94.9
                        Vancomycin                59                \>16          \>32             \>16 to \>32    0.0                                       0.0
      E. faecalis, VS   Eravacycline              1,505             0.06          0.06             0.008 to 0.5    94.8[^*a*^](#T3F1){ref-type="table-fn"}   99.5
                        Amoxicillin-clavulanate   1,505             1             1                ≤0.12 to \>1    NA                                        100[^*b*^](#T3F2){ref-type="table-fn"}
                        Ampicillin                1,046             1             2                ≤0.25 to \>8    99.3                                      99.3
                        Azithromycin              459               \>8           \>8              ≤0.12 to \>8    NA                                        NA
                        Ceftriaxone               459               \>64          \>64             ≤0.5 to \>64    NA                                        NA
                        Daptomycin                1,505             1             2                ≤0.06 to 8      94.3                                      NA
                        Levofloxacin              1,505             1             \>8              ≤0.03 to \>8    71.8                                      72.2
                        Linezolid                 1,505             2             2                ≤0.5 to \>4     99.5                                      99.9
                        Minocycline               1,505             \>8           \>8              ≤0.03 to \>8    28.1                                      NA
                        Penicillin                1,505             2             4                ≤0.12 to \>8    97.7                                      NA
                        Tetracycline              1,505             \>32          \>32             ≤0.06 to \>32   22.6                                      NA
                        Tigecycline               1,505             0.12          0.25             ≤0.015 to 8     94.8[^*a*^](#T3F1){ref-type="table-fn"}   94.8
                        Vancomycin                1,505             1             2                0.12 to 4       100                                       100
  E. faecium            Eravacycline              1,221             0.03          0.06             0.008 to 1      95.0[^*a*^](#T3F1){ref-type="table-fn"}   97.7
                        Amoxicillin-clavulanate   1,221             \>1           \>1              ≤0.12 to \>1    NA                                        67.2[^*b*^](#T3F2){ref-type="table-fn"}
                        Ampicillin                762               \>8           \>8              ≤0.25 to \>8    11.8                                      11.2
                        Azithromycin              459               \>8           \>8              0.25 to \>8     NA                                        NA
                        Ceftriaxone               459               \>64          \>64             1 to \>64       NA                                        NA
                        Daptomycin                1,221             4             4                ≤0.06 to \>8    47.5                                      NA
                        Levofloxacin              1,221             \>8           \>8              0.06 to \>8     8.9                                       13.1
                        Linezolid                 1,221             2             2                ≤0.5 to \>8     98.1                                      99.4
                        Minocycline               1,221             4             \>8              ≤0.03 to \>8    50.9                                      NA
                        Penicillin                1,221             \>8           \>8              ≤0.06 to \>8    10.4                                      NA
                        Tetracycline              1,221             32            \>32             ≤0.06 to \>32   40.8                                      NA
                        Tigecycline               1,221             0.12          0.25             ≤0.015 to 8     95.2[^*a*^](#T3F1){ref-type="table-fn"}   95.2
                        Vancomycin                1,219             1             \>32             ≤0.12 to \>32   57.6                                      57.6
      E. faecium, VR    Eravacycline              510               0.03          0.06             0.008 to 1      93.1[^*a*^](#T3F1){ref-type="table-fn"}   96.1
                        Amoxicillin-clavulanate   510               \>1           \>1              ≤0.12 to \>1    NA                                        51.4[^*b*^](#T3F2){ref-type="table-fn"}
                        Ampicillin                256               \>8           \>8              0.5 to \>8      0.8                                       0.8
                        Azithromycin              254               \>8           \>8              0.25 to \>8     NA                                        NA
                        Ceftriaxone               254               \>64          \>64             1 to \>64       NA                                        NA
                        Daptomycin                510               2             4                0.12 to 8       50.4                                      NA
                        Levofloxacin              510               \>8           \>8              2 to \>8        0.2                                       0.2
                        Linezolid                 510               2             2                ≤0.5 to \>8     98.0                                      98.8
                        Minocycline               510               8             \>8              ≤0.03 to \>8    42.8                                      NA
                        Penicillin                510               \>8           \>8              0.5 to \>8      1.0                                       NA
                        Tetracycline              510               32            \>32             0.12 to \>32    26.1                                      NA
                        Tigecycline               510               0.12          0.25             0.03 to 4       93.7[^*a*^](#T3F1){ref-type="table-fn"}   93.7
                        Vancomycin                510               \>16          \>32             \>16 to \>32    0.0                                       0.0
      E. faecium, VS    Eravacycline              702               0.03          0.06             0.008 to 0.5    96.3[^*a*^](#T3F1){ref-type="table-fn"}   98.9
                        Amoxicillin-clavulanate   702               \>1           \>1              ≤0.12 to \>1    NA                                        79.2[^*b*^](#T3F2){ref-type="table-fn"}
                        Ampicillin                504               \>8           \>8              ≤0.25 to \>8    17.5                                      16.5
                        Azithromycin              198               \>8           \>8              0.25 to \>8     NA                                        NA
                        Ceftriaxone               198               \>64          \>64             1 to \>64       NA                                        NA
                        Daptomycin                702               4             4                ≤0.06 to 8      45.6                                      NA
                        Levofloxacin              702               \>8           \>8              0.06 to \>8     15.4                                      22.7
                        Linezolid                 702               2             2                ≤0.5 to 8       98.2                                      99.9
                        Minocycline               702               1             \>8              ≤0.03 to \>8    56.8                                      NA
                        Penicillin                702               \>8           \>8              ≤0.06 to \>8    17.4                                      NA
                        Tetracycline              702               1             \>32             ≤0.06 to \>32   51.4                                      NA
                        Tigecycline               702               0.12          0.12             ≤0.015 to 8     96.2[^*a*^](#T3F1){ref-type="table-fn"}   96.2
                        Vancomycin                702               1             1                ≤0.12 to 4      100                                       100
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U.S. Food and Drug Administration (FDA) MIC interpretative susceptible breakpoints were used in place of CLSI MIC breakpoints for eravacycline (≤0.06 μg/ml) and tigecycline (≤0.25 μg/ml) ([@B21]), as none currently exist. FDA tigecycline breakpoints for vancomycin-susceptible E. faecalis were also applied to vancomycin-resistant isolates and to E. faecium.

EUCAST breakpoints were applied for amoxicillin-clavulanate, although these are based on susceptibility testing using a fixed concentration of clavulanic acid of 2 μg/ml, while for this study, amoxicillin-clavulanate was tested with a 2:1 ratio.

VR, vancomycin resistant; VS, vancomycin susceptible; NA, MIC breakpoint not available.

###### 

*In vitro* activity of eravacycline and comparator agents against streptococci, cumulative 2013 to 2017 data[^*g*^](#T4F7){ref-type="table-fn"}

  Organism                                                Drug                      No. of isolates   MIC (μg/ml)   \% susceptible                                                               
  ------------------------------------------------------- ------------------------- ----------------- ------------- ---------------- ----------------- ----------------------------------------- -----------------------------------------
  S. pneumoniae                                           Eravacycline              596               0.008         0.015            ≤0.001 to 0.03    NA                                        NA
                                                          Amoxicillin-clavulanate   491               0.06          4                ≤0.015 to \>4     83.5                                      NA
                                                          Azithromycin              596               0.12          \>2              ≤0.03 to \>2      58.9                                      58.4
                                                          Ceftaroline               105               0.008         0.12             ≤0.004 to 0.5     100                                       98.1
                                                          Ceftriaxone               596               0.03          1                ≤0.015 to \>2     92.3                                      82.4
                                                          Clindamycin               105               0.03          \>1              ≤0.015 to \>1     74.3                                      74.3
                                                          Daptomycin                595               0.12          0.25             ≤0.03 to 1        NA                                        NA
                                                          Levofloxacin              596               1             1                ≤0.25 to \>8      99.0                                      99.0
                                                          Linezolid                 596               1             2                ≤0.12 to 2        100                                       100
                                                          Meropenem                 105               ≤0.03         \>0.5            ≤0.03 to \>0.5    78.1                                      ---
                                                          Minocycline               596               ≤0.06         8                ≤0.06 to \>8      NA                                        75.8
                                                          Penicillin                596               ≤0.12         2                ≤0.12 to \>2      48.0[^*b*^](#T4F2){ref-type="table-fn"}   48.0[^*b*^](#T4F2){ref-type="table-fn"}
                                                          Tetracycline              596               0.12          \>4              ≤0.03 to \>4      74.8                                      74.8
                                                          Tigecycline               596               ≤0.008        0.06             ≤0.008 to 0.25    98.2[^*a*^](#T4F1){ref-type="table-fn"}   NA
                                                          Vancomycin                105               0.25          0.5              ≤0.06 to 0.5      100                                       100
  S. agalactiae                                           Eravacycline              1,239             0.03          0.06             0.008 to 0.25     98.0[^*c*^](#T4F3){ref-type="table-fn"}   99.8[^*d*^](#T4F4){ref-type="table-fn"}
                                                          Amoxicillin-clavulanate   598               0.12          0.12             0.03 to 0.5       NA                                        NA
                                                          Azithromycin              1,239             0.12          \>1              ≤0.03 to \>2      63.7                                      63.6
                                                          Ceftaroline               641               0.015         0.015            ≤0.004 to 0.12    100                                       NA
                                                          Ceftriaxone               1,239             0.06          0.12             ≤0.015 to 0.5     100                                       NA
                                                          Clindamycin               1,040             0.06          \>1              ≤0.015 to \>1     74.5                                      75.9
                                                          Daptomycin                1,239             0.25          0.5              0.06 to 1         100                                       100
                                                          Levofloxacin              1,239             1             1                ≤0.25 to \>8      96.5                                      96.5
                                                          Linezolid                 1,239             1             2                0.25 to 2         100                                       100
                                                          Meropenem                 1,040             0.06          0.12             ≤0.03 to 0.25     100                                       NA
                                                          Minocycline               1,239             \>8           \>8              ≤0.06 to \>8      NA                                        19.9
                                                          Penicillin                1,239             ≤0.12         ≤0.12            ≤0.12 to 0.5      99.6                                      99.8
                                                          Tetracycline              1,239             \>4           \>4              0.06 to \>4       20.3                                      20.2
                                                          Tigecycline               1,239             0.06          0.06             ≤0.008 to 0.25    100[^*c*^](#T4F3){ref-type="table-fn"}    99.8
                                                          Vancomycin                1,040             0.5           0.5              0.25 to 1         100                                       100
  S. pyogenes                                             Eravacycline              1,192             0.03          0.03             0.004 to 0.06     100[^*c*^](#T4F3){ref-type="table-fn"}    100[^*d*^](#T4F4){ref-type="table-fn"}
                                                          Amoxicillin-clavulanate   665               0.03          0.03             ≤0.015 to 0.25    NA                                        NA
                                                          Azithromycin              1,192             0.12          0.5              ≤0.03 to \>2      90.1                                      89.9
                                                          Ceftaroline               527               ≤0.004        0.008            ≤0.004 to 0.015   100                                       NA
                                                          Ceftriaxone               1,192             0.03          0.03             ≤0.015 to 1       99.9                                      NA
                                                          Clindamycin               869               0.06          0.06             ≤0.015 to \>1     94.8                                      94.9
                                                          Daptomycin                1,192             0.06          0.06             ≤0.03 to 0.25     100                                       100
                                                          Levofloxacin              1,192             0.5           1                ≤0.25 to \>4      99.6                                      99.6
                                                          Linezolid                 1,192             1             2                ≤0.12 to 2        100                                       100
                                                          Meropenem                 869               ≤0.03         ≤0.03            ≤0.03 to 0.12     100                                       NA
                                                          Minocycline               1,192             0.12          4                ≤0.06 to \>8      NA                                        86.9
                                                          Penicillin                1,192             ≤0.12         ≤0.12            ≤0.12 to ≤0.12    100                                       100
                                                          Tetracycline              1,192             0.25          \>4              ≤0.03 to \>4      86.9                                      86.7
                                                          Tigecycline               1,192             0.03          0.06             ≤0.008 to 0.12    100[^*c*^](#T4F3){ref-type="table-fn"}    100
                                                          Vancomycin                869               0.5           0.5              ≤0.06 to 1        100                                       100
  S. anginosus group[^*e*^](#T4F5){ref-type="table-fn"}   Eravacycline              346               0.03          0.06             ≤0.001 to 0.12    99.1[^*c*^](#T4F3){ref-type="table-fn"}   100
                                                          Amoxicillin-clavulanate   138               0.06          0.25             ≤0.015 to 2       NA                                        NA
                                                          Azithromycin              346               0.06          \>1              ≤0.03 to \>2      81.2                                      NA
                                                          Ceftaroline               208               0.015         0.03             ≤0.004 to 0.25    NA                                        NA
                                                          Ceftriaxone               346               0.12          0.25             ≤0.015 to \>2     99.4                                      99.1
                                                          Clindamycin               266               0.03          0.06             ≤0.015 to \>1     91.0                                      91.0
                                                          Daptomycin                346               0.25          0.5              ≤0.03 to 1        100                                       NA
                                                          Levofloxacin              346               0.5           1                ≤0.25 to \>4      99.4                                      NA
                                                          Linezolid                 346               1             2                ≤0.12 to 2        100                                       NA
                                                          Meropenem                 266               ≤0.03         0.12             ≤0.03 to 0.5      100                                       100
                                                          Minocycline               346               ≤0.06         8                ≤0.06 to \>8      NA                                        NA
                                                          Penicillin                346               ≤0.12         ≤0.12            ≤0.12 to 1        95.4                                      98.0
                                                          Tetracycline              346               0.25          \>4              ≤0.03 to \>4      69.9                                      NA
                                                          Tigecycline               346               0.03          0.06             ≤0.008 to 0.5     99.7[^*c*^](#T4F3){ref-type="table-fn"}   99.1[^*f*^](#T4F6){ref-type="table-fn"}
                                                          Vancomycin                266               0.5           1                ≤0.06 to 1        100                                       100
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U.S. Food and Drug Administration (FDA) MIC interpretative breakpoints were used in place of CLSI MIC breakpoints for tigecycline (≤0.06 μg/ml) ([@B21]), as none currently exist.

Determined using the CLSI susceptible breakpoint for oral penicillin and EUCAST susceptible breakpoint for benzylpenicillin indications other than meningitis (≤0.06 μg/ml).

U.S. Food and Drug Administration (FDA) MIC interpretative susceptible breakpoints were used in place of CLSI MIC breakpoints for eravacycline (≤0.06 μg/ml) and tigecycline (≤0.25 μg/ml) ([@B21]), as none currently exist. The FDA eravacycline susceptible breakpoint for the S. anginosus group was applied to beta-hemolytic streptococci.

The EUCAST eravacycline susceptible breakpoint for the S. anginosus group (≤0.12 μg/ml) was applied to beta-hemolytic streptococci.

The S. anginosus group (*n* = 346) includes S. anginosus (*n* = 302), S. constellatus (*n* = 36), S. intermedius (*n* = 7), and S. intermedius/S. milleri (*n* = 1).

EUCAST tigecycline breakpoints for beta-hemolytic streptococci (≤0.12 μg/ml) were applied to the S. anginosus group.

NA, MIC breakpoint not available; ---, not evaluable, as the tested MIC range did not extend high enough for the EUCAST susceptible breakpoint for S. pneumoniae.

When isolates were allocated to their respective geographic regions, eravacycline MIC~90~s were within 1 doubling dilution for all Gram-positive genera/species (see Table S3 in the supplemental material). Similarly, there were no significant differences (a \>1-doubling-dilution increase or decrease in MIC~90~s) observed in the *in vitro* activity of eravacycline for any genera/species of Gram-positive bacteria stratified by study period (2013 to 2014, 2015, 2016, 2017) (Table S4) or stratified by specimen source (Table S5). A detailed trend analysis could not be conducted, given that there were changes in participating laboratories and the panel of antimicrobial agents tested over the time period studied (2013 to 2017). Overall, eravacycline activity was similar over time and across geographic regions and specimen sources.

Eravacycline consistently demonstrated 2- to 4-fold lower MIC~90~ values than tigecycline for populations of Gram-positive pathogens. Previous *in vitro* studies comparing eravacycline and tigecycline have reported similar 2- to 4-fold improvements in the MIC~90~ ([@B4], [@B6], [@B7], [@B15]). Susceptibility rates, due to a difference in breakpoints, were similar between these two antibiotics. As tigecycline EUCAST breakpoints have recently been lowered for Gram-negative organisms, perhaps a review of the breakpoints for Gram-positive organisms is also warranted for this agent.

This global surveillance investigation highlights the broad-spectrum potency of eravacycline against Gram-positive bacteria, including resistant isolates. As cIAIs are well-known to be polymicrobial, involving synergistic Gram-positive, Gram-negative, and anaerobic organism interactions, this study underscores the potential benefit of eravacycline for the empirical treatment of cIAIs. Furthermore, eravacycline may have a role in the treatment of other infections caused predominantly by Gram-positive pathogens, but the clinical utility in such disease states should be investigated.

MATERIALS AND METHODS {#s3}
=====================

Bacterial isolates. {#s3.1}
-------------------

From 2013 to 2017, 10,511 clinical isolates of *Enterococcus* spp. (*n* = 2,807), *Staphylococcus* spp. (*n* = 4,331), and *Streptococcus* spp. (*n* = 3,373) were collected by laboratories in 37 countries on three continents (Asia/Pacific, Europe, North America). The identity of each isolate was confirmed using matrix-assisted laser desorption ionization--time of flight (MALDI-TOF) mass spectrometry (Bruker Biotyper; Bruker Daltonics, Bremen, Germany).

Table S1 in the supplemental material summarizes the numbers of isolates collected in each of the four study periods (2013 to 2014, 2015, 2016, and 2017) by geographic region. Overall, approximately 54% of the isolates came from Europe, 35% of the isolates came from North America, and 10% came from the Asia-Pacific region. In total, there were 3,180, 2,082, 3,176, 956, and 1,117 isolates, respectively, from respiratory, intra-abdominal, urinary, skin, and other specimen sources (Table S2).

Isolates were limited to one per patient, determined by the participating laboratory algorithms to be clinically significant, and collected irrespective of their antimicrobial susceptibility profile and independent of patient gender or age. The study was not designed to directly compare the prevalence of antimicrobial-resistant pathogens across specific geographic locations but, rather, was designed to evaluate the *in vitro* activities of eravacycline and the comparator antimicrobial agents against a global collection of frequently encountered clinical isolates of Gram-positive bacteria collected from 2013 to 2017.

Antimicrobial susceptibility testing. {#s3.2}
-------------------------------------

The *in vitro* susceptibilities of the isolates were determined using the CLSI-defined broth microdilution method in 96-well broth microdilution panels ([@B18], [@B19]). The antimicrobial agents used in panel production were acquired as laboratory-grade powders from their respective manufacturers or from a commercial source. The list of antimicrobial agents tested in each of the four study periods varied slightly, in that some agents, in addition to those tested in the 2013 to 2014 period, were included in the 2015, 2016, and 2017 testing periods. Of note, ampicillin, clindamycin, meropenem, and oxacillin were tested only in 2015, 2016, and 2017. The eravacycline MICs for Gram-positive bacteria were read following the current CLSI standard for dilution method testing; MIC endpoints were read following panel incubation at 35°C in ambient air for 16 to 20 h (*Enterococcus* and *Staphylococcus* spp.) or 35°C in ambient air for 20 to 24 h (*Streptococcus* spp.) ([@B19]). Quality control testing for eravacycline and the other antimicrobial agents was performed on each day of testing, as specified by the CLSI, using the CLSI-defined control strains E. faecalis ATCC 29212, S. aureus ATCC 29213, and S. pneumoniae ATCC 49619 ([@B19]).

MICs were interpreted using 2019 CLSI MIC breakpoints ([@B19]) and 2019 EUCAST MIC breakpoints ([@B20]), with the following exceptions. FDA MIC interpretative breakpoints were used for tigecycline ([@B21]) and eravacycline in place of CLSI MIC breakpoints, which are not currently published for these agents. Additionally, tigecycline breakpoints for vancomycin-susceptible Enterococcus faecalis were applied to vancomycin-resistant isolates and to Enterococcus faecium; EUCAST eravacycline breakpoints for the Streptococcus anginosus group were applied to beta-hemolytic streptococci; EUCAST tigecycline breakpoints for beta-hemolytic streptococci were applied to the S. anginosus group; and EUCAST eravacycline breakpoints for S. aureus were applied to coagulase-negative *Staphylococcus* species.
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Supplemental material is available online only.
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